Top

Published in:

Open Access 01-12-2024 | Human Papillomavirus | Review

Cervicovaginal microbiota: a promising direction for prevention and treatment in cervical cancer

Authors: Jie Shen, Hao Sun, Jing Chu, Xiaodi Gong, Xiaojun Liu

Published in: Infectious Agents and Cancer | Issue 1/2024

Abstract

Cervical cancer is a common malignancy in women, with high incidence rate and mortality. Persistent infection of high-risk human papillomavirus (HPV) is the most important risk factor for cervical cancer and precancerous lesions. Cervicovaginal microbiota (CVM) plays an essential role in the defense of HPV infections and prevention of subsequent lesions. Dominance of Lactobacillus is the key of CVM homeostasis, which can be regulated by host, exogenous and endogenous factors. Dysbiosis of CVM, including altered microbial, metabolic, and immune signatures, can contribute to persist HPV infection, leading to cervical cancer. However, there is no evidence of the causality between CVM and cervical cancer, and the underlying mechanism remains unexplored. Considering the close correlation between CVM dysbiosis and persistent HPV infection, this review will overview CVM, its role in cervical cancer development and related mechanisms, and the prospects for therapeutic applications.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197–206. https://doi.org/10.1016/S2214-109X(22)00501-0.CrossRefPubMed

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. https://doi.org/10.3322/caac.21820.CrossRefPubMed

Cascardi E, Cazzato G, Daniele A, et al. Association between Cervical Microbiota and HPV: could this be the Key to complete. Cerv Cancer Eradication? Biology. 2022;11(8):1114. https://doi.org/10.3390/biology11081114.CrossRef

Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019;393(10167):169–82. https://doi.org/10.1016/S0140-6736(18)32470-X.CrossRefPubMed

Trifanescu OG, Trifanescu RA, Mitrica RI, et al. The Female Reproductive Tract Microbiome and Cancerogenesis: a Review story of Bacteria, hormones, and Disease. Diagnostics (Basel). 2023;13(5):877. https://doi.org/10.3390/diagnostics13050877.CrossRefPubMed

Salinas AM, Osorio VG, Pacha-Herrera D, et al. Vaginal microbiota evaluation and prevalence of key pathogens in Ecuadorian women: an epidemiologic analysis. Sci Rep. 2020;10(1):18358. https://doi.org/10.1038/s41598-020-74655-z.CrossRefPubMedPubMedCentral

Moscicki AB, Shi B, Huang H, et al. Cervical-vaginal Microbiome and Associated Cytokine profiles in a prospective study of HPV 16 Acquisition, persistence, and Clearance. Front Cell Infect Microbiol. 2020;10:569022. https://doi.org/10.3389/fcimb.2020.569022.CrossRefPubMedPubMedCentral

Wang Y, Wang X, Zhu M, et al. The interplay between Cervicovaginal Microbial Dysbiosis and Cervicovaginal Immunity. Front Immunol. 2022;13:857299. https://doi.org/10.3389/fimmu.2022.857299.CrossRefPubMedPubMedCentral

10.

Zhai Q, Zhang W, Zhang Z, et al. Characteristics of the Cervicovaginal Microenvironment in Childbearing-Age women with different degrees of cervical lesions and HR-HPV positivity. Pol J Microbiol. 2021;70(4):489–500. https://doi.org/10.33073/pjm-2021-046.CrossRefPubMedPubMedCentral

11.

Wei B, Chen Y, Lu T, et al. Correlation between vaginal microbiota and different progression stages of cervical cancer. Genet Mol Biol. 2022;45(2):e20200450. https://doi.org/10.1590/1678-4685-gmb-2020-0450.CrossRefPubMedPubMedCentral

12.

Xia C, Su J, Liu C et al. Human microbiomes in cancer development and therapy. MedComm (2020). 2023;4(2):e221. https://doi.org/10.1002/mco2.221.

13.

Laniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol. 2020;17(4):232–50. https://doi.org/10.1038/s41585-020-0286-z.CrossRefPubMedPubMedCentral

14.

Pacha-Herrera D, Vasco G, Cruz-Betancourt C, et al. Vaginal microbiota evaluation and Lactobacilli quantification by qPCR in pregnant and non-pregnant women: a pilot study. Front Cell Infect Microbiol. 2020;10:303. https://doi.org/10.3389/fcimb.2020.00303.CrossRefPubMedPubMedCentral

15.

Dong M, Dong Y, Bai J, et al. Interactions between microbiota and cervical epithelial, immune, and mucus barrier. Front Cell Infect Microbiol. 2023;13:1124591. https://doi.org/10.3389/fcimb.2023.1124591.CrossRefPubMedPubMedCentral

16.

Zhang Z, Li T, Zhang D, et al. Distinction between vaginal and cervical microbiota in high-risk human papilloma virus-infected women in China. BMC Microbiol. 2021;21(1):90. https://doi.org/10.1186/s12866-021-02152-y.CrossRefPubMedPubMedCentral

17.

Wang R, Zhou G, Wu L, et al. The Microbial composition of Lower Genital Tract May affect the outcome of in vitro fertilization-embryo transfer. Front Microbiol. 2021;12:729744. https://doi.org/10.3389/fmicb.2021.729744.CrossRefPubMedPubMedCentral

18.

Anahtar MN, Gootenberg DB, Mitchell CM, et al. Cervicovaginal Microbiota and Reproductive Health: the Virtue of simplicity. Cell Host Microbe. 2018;23(2):159–68. https://doi.org/10.1016/j.chom.2018.01.013.CrossRefPubMed

19.

Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci. 2011;108(supplement1):4680–7. https://doi.org/10.1073/pnas.1002611107.CrossRefPubMed

20.

France MT, Ma B, Gajer P, et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. Microbiome. 2020;8(1):166. https://doi.org/10.1186/s40168-020-00934-6.CrossRefPubMedPubMedCentral

21.

Nouioui I, Carro L, García-López M, et al. Genome-based taxonomic classification of the Phylum Actinobacteria. Front Microbiol. 2018;9:2007. https://doi.org/10.3389/fmicb.2018.02007.CrossRefPubMedPubMedCentral

22.

Sun N, Ding H, Yu H, et al. Comprehensive characterization of Microbial Community in the female genital tract of Reproductive-aged women in China. Front Cell Infect Microbiol. 2021;11:649067. https://doi.org/10.3389/fcimb.2021.649067.CrossRefPubMedPubMedCentral

23.

Lebeer S, Ahannach S, Gehrmann T, et al. A citizen-science-enabled catalogue of the vaginal microbiome and associated factors. Nat Microbiol. 2023;8(11):2183–95. https://doi.org/10.1038/s41564-023-01500-0.CrossRefPubMedPubMedCentral

24.

Baker JM, Chase DM, Herbst-Kralovetz MM. Uterine microbiota: residents, tourists, or invaders? Front Immunol. 2018;9:208. https://doi.org/10.3389/fimmu.2018.00208.CrossRefPubMedPubMedCentral

25.

Winters AD, Romero R, Gervasi MT, et al. Does the endometrial cavity have a molecular microbial signature? Sci Rep. 2019;9(1):9905. https://doi.org/10.1038/s41598-019-46173-0.CrossRefPubMedPubMedCentral

26.

Shen L, Wang W, Hou W, et al. The function and mechanism of action of uterine microecology in pregnancy immunity and its complications. Front Cell Infect Microbiol. 2023;12:1025714. https://doi.org/10.3389/fcimb.2022.1025714.CrossRefPubMedPubMedCentral

27.

Kaur H, Merchant M, Haque MM, et al. Crosstalk between Female Gonadal Hormones and vaginal microbiota across various phases of women’s gynecological lifecycle. Front Microbiol. 2020;11:551. https://doi.org/10.3389/fmicb.2020.00551.CrossRefPubMedPubMedCentral

28.

Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2012;4(132):132ra52. https://doi.org/10.1126/scitranslmed.3003605.CrossRefPubMedPubMedCentral

29.

McKinnon LR, Achilles SL, Bradshaw CS, et al. The evolving facets of bacterial vaginosis: implications for HIV Transmission. AIDS Res Hum Retroviruses. 2019;35(3):219–28. https://doi.org/10.1089/aid.2018.0304.CrossRefPubMedPubMedCentral

30.

Song SD, Acharya KD, Zhu JE, et al. Daily Vaginal Microbiota fluctuations Associated with Natural Hormonal cycle, contraceptives, Diet, and Exercise. mSphere. 2020;5(4):e520–93. https://doi.org/10.1128/mSphere.00593-20.CrossRef

31.

Łaniewski P, Barnes D, Goulder A, et al. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-hispanic and hispanic women. Sci Rep. 2018;8(1):7593. https://doi.org/10.1038/s41598-018-25879-7.CrossRefPubMedPubMedCentral

32.

Onywera H, Williamson A, Mbulawa ZZA, et al. Factors associated with the composition and diversity of the cervical microbiota of reproductive-age black South African women: a retrospective cross-sectional study. PeerJ. 2019;7:e7488. https://doi.org/10.7717/peerj.7488.CrossRefPubMedPubMedCentral

33.

Moosa Y, Kwon D, de Oliveira T, et al. Determinants of vaginal microbiota composition. Front Cell Infect Microbiol. 2020;10:467. https://doi.org/10.3389/fcimb.2020.00467.CrossRefPubMedPubMedCentral

34.

Kyrgiou M, Mitra A, Moscicki A. Does the vaginal microbiota play a role in the development of cervical cancer? Transl Res. 2017;179:168–82. https://doi.org/10.1016/j.trsl.2016.07.004.CrossRefPubMed

35.

Amabebe E, Anumba DOC. The Vaginal Microenvironment: the physiologic role of Lactobacilli. Front Med (Lausanne). 2018;5:181. https://doi.org/10.3389/fmed.2018.00181.CrossRefPubMed

36.

Krog MC, Hugerth LW, Fransson E, et al. The healthy female microbiome across body sites: effect of hormonal contraceptives and the menstrual cycle. Hum Reprod. 2022;37(7):1525–43. https://doi.org/10.1093/humrep/deac094.CrossRefPubMedPubMedCentral

37.

Oerlemans E, Ahannach S, Wittouck S, et al. Impacts of Menstruation, Community Type, and an oral yeast Probiotic on the vaginal microbiome. mSphere. 2022;7(5):e222–39. https://doi.org/10.1128/msphere.00239-22.CrossRef

38.

Jie Z, Chen C, Hao L, et al. Life history recorded in the Vagino-cervical Microbiome along with multi-omes. Genomics Proteom Bioinf. 2022;20(2):304–21. https://doi.org/10.1016/j.gpb.2021.01.005.CrossRef

39.

Balle C, Konstantinus IN, Jaumdally SZ, et al. Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial. Nat Commun. 2020;11(1):5578. https://doi.org/10.1038/s41467-020-19382-9.CrossRefPubMedPubMedCentral

40.

Kim S, Seo H, Rahim MA et al. Changes in the Microbiome of Vaginal Fluid after Menopause in Korean Women. J Microbiol Biotechnol. 20218;31(11):1490–500. https://doi.org/10.4014/jmb.2106.06022.

41.

Gliniewicz K, Schneider GM, Ridenhour BJ, et al. Comparison of the Vaginal microbiomes of Premenopausal and Postmenopausal women. Front Microbiol. 2019;10:193. https://doi.org/10.3389/fmicb.2019.00193.CrossRefPubMedPubMedCentral

42.

Romero R, Hassan SS, Gajer P, et al. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome. 2014;2(1):4. https://doi.org/10.1186/2049-2618-2-4.CrossRefPubMedPubMedCentral

43.

Freitas AC, Chaban B, Bocking A, et al. The vaginal microbiome of pregnant women is less rich and diverse, with lower prevalence of Mollicutes, compared to non-pregnant women. Sci Rep. 2017;7(1):9212. https://doi.org/10.1038/s41598-017-07790-9.CrossRefPubMedPubMedCentral

44.

Gupta P, Singh MP, Goyal K. Diversity of vaginal microbiome in pregnancy: deciphering the Obscurity. Front Public Health. 2020;8:326. https://doi.org/10.3389/fpubh.2020.00326.CrossRefPubMedPubMedCentral

45.

Salinas AM, Osorio VG, Endara PF, et al. Bacterial identification of the vaginal microbiota in Ecuadorian pregnant teenagers: an exploratory analysis. PeerJ. 2018;6:e4317. https://doi.org/10.7717/peerj.4317.CrossRefPubMedPubMedCentral

46.

Brooks JP, Edwards DJ, Blithe DL, et al. Effects of combined oral contraceptives, depot medroxyprogesterone acetate and the levonorgestrel-releasing intrauterine system on the vaginal microbiome. Contraception. 2017;95(4):405–13. https://doi.org/10.1016/j.contraception.2016.11.006.CrossRefPubMed

47.

Vodstrcil LA, Plummer ME, Fairley CK, et al. Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Sci Rep. 2019;9(1):3555. https://doi.org/10.1038/s41598-019-39879-8.CrossRefPubMedPubMedCentral

48.

Tuddenham S, Gajer P, Burke AE, et al. Lactobacillus-dominance and rapid stabilization of vaginal microbiota in combined oral contraceptive pill users examined through a longitudinal cohort study with frequent vaginal sampling over two years. EBioMedicine. 2023;87:104407. https://doi.org/10.1016/j.ebiom.2022.104407.CrossRefPubMed

49.

Donders G, Bellen G, Janssens D, et al. Influence of contraceptive choice on vaginal bacterial and fungal microflora. Eur J Clin Microbiol Infect Dis. 2017;36(1):43–8. https://doi.org/10.1007/s10096-016-2768-8.CrossRefPubMed

50.

Achilles SL, Hillier SL. The complexity of contraceptives. AIDS. 2013;27(Supplement 1):S5–15. https://doi.org/10.1097/QAD.0000000000000058.CrossRefPubMed

51.

Achilles SL, Austin MN, Meyn LA, et al. Impact of contraceptive initiation on vaginal microbiota. Am J Obstet Gynecol. 2018;218(6):621–2. https://doi.org/10.1016/j.ajog.2018.02.017.CrossRef

52.

Fichorova RN, Chen P, Morrison CS, et al. The contribution of Cervicovaginal Infections to the Immunomodulatory effects of Hormonal Contraception. mBio. 2015;6(5):e215–21. https://doi.org/10.1128/mBio.00221-15.CrossRef

53.

Tamma R, Annese T, Ruggieri S, et al. Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. Eur J Clin Invest. 2019;49(5):e13087. https://doi.org/10.1111/eci.13087.CrossRefPubMed

54.

Yang X, Guo Y, Chen C, et al. Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment. Immunology. 2021;164(3):476–93. https://doi.org/10.1111/imm.13397.CrossRefPubMedPubMedCentral

55.

Brotman RM, He X, Gajer P, et al. Association between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infect Dis. 2014;14:471. https://doi.org/10.1186/1471-2334-14-471.CrossRefPubMedPubMedCentral

56.

Nelson TM, Borgogna JC, Michalek RD, et al. Cigarette smoking is associated with an altered vaginal tract metabolomic profile. Sci Rep. 2018;8(1):852. https://doi.org/10.1038/s41598-017-14943-3.CrossRefPubMedPubMedCentral

57.

Cangui-Panchi SP, Ñacato-Toapanta AL, Enríquez-Martínez LJ, et al. Battle royale: Immune response on biofilms - host-pathogen interactions. Curr Res Immunol. 2023;4:100057. https://doi.org/10.1016/j.crimmu.2023.100057.CrossRefPubMedPubMedCentral

58.

Scillato M, Spitale A, Mongelli G, et al. Antimicrobial properties of Lactobacillus cell-free supernatants against multidrug-resistant urogenital pathogens. Microbiologyopen. 2021;10(2):e1173. https://doi.org/10.1002/mbo3.1173.CrossRefPubMedPubMedCentral

59.

Tamarelle J, Thiébaut ACM, de Barbeyrac B, et al. The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(1):35–47. https://doi.org/10.1016/j.cmi.2018.04.019.CrossRefPubMed

60.

Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 2020;19(1):5. https://doi.org/10.1186/s12941-020-0347-4.CrossRefPubMedPubMedCentral

61.

Yang X, Da M, Zhang W, et al. Role of Lactobacillus in cervical cancer. Cancer Manag Res. 2018;10:1219–29. https://doi.org/10.2147/CMAR.S165228.CrossRefPubMedPubMedCentral

62.

De Gregorio PR, Parolin C, Abruzzo A, et al. Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion. Microb Cell Fact. 2020;19(1):133. https://doi.org/10.1186/s12934-020-01390-5.CrossRefPubMedPubMedCentral

63.

Pacha-Herrera D, Erazo-Garcia MP, Cueva DF, et al. Clustering analysis of the Multi-microbial Consortium by Lactobacillus species against vaginal dysbiosis among Ecuadorian women. Front Cell Infect Microbiol. 2022;12:863208. https://doi.org/10.3389/fcimb.2022.863208.CrossRefPubMedPubMedCentral

64.

Jung H, Ehlers MM, Peters RPH, et al. Growth forms of Gardnerella spp. and Lactobacillus spp. on vaginal cells. Front Cell Infect Microbiol. 2020;10:71. https://doi.org/10.3389/fcimb.2020.00071.CrossRefPubMedPubMedCentral

65.

Pendharkar S, Skafte-Holm A, Simsek G, et al. Lactobacilli and their probiotic effects in the Vagina of Reproductive Age women. Microorganisms. 2023;11(3):636. https://doi.org/10.3390/microorganisms11030636.CrossRefPubMedPubMedCentral

66.

Rodríguez-Arias RJ, Guachi-Álvarez BO, Montalvo-Vivero DE, et al. Lactobacilli displacement and Candida albicans inhibition on initial adhesion assays: a probiotic analysis. BMC Res Notes. 2022;15(1):239. https://doi.org/10.1186/s13104-022-06114-z.CrossRefPubMedPubMedCentral

67.

Atassi F, Pho Viet Ahn DL, Lievin-Le Moal V. Diverse expression of Antimicrobial Activities against Bacterial Vaginosis and urinary tract infection pathogens by Cervicovaginal Microbiota strains of Lactobacillus gasseri and Lactobacillus crispatus. Front Microbiol. 2019;10:2900. https://doi.org/10.3389/fmicb.2019.02900.CrossRefPubMedPubMedCentral

68.

Chee W, Chew SY, Than L. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microb Cell Fact. 2020;19(1):203. https://doi.org/10.1186/s12934-020-01464-4.CrossRefPubMedPubMedCentral

69.

Shannon B, Yi TJ, Perusini S, et al. Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal Immunol. 2017;10(5):1310–9. https://doi.org/10.1038/mi.2016.129.CrossRefPubMedPubMedCentral

70.

Han M, Wang N, Han W, et al. Vaginal and tumor microbiomes in gynecological cancer (review). Oncol Lett. 2023;25(4):153. https://doi.org/10.3892/ol.2023.13739.CrossRefPubMedPubMedCentral

71.

Gao Q, Fan T, Luo S, et al. Lactobacillus gasseri LGV03 isolated from the cervico-vagina of HPV-cleared women modulates epithelial innate immune responses and suppresses the growth of HPV-positive human cervical cancer cells. Transl Oncol. 2023;35:101714. https://doi.org/10.1016/j.tranon.2023.101714.CrossRefPubMedPubMedCentral

72.

Sungur T, Aslim B, Karaaslan C, et al. Impact of Exopolysaccharides (EPSs) of Lactobacillus gasseri strains isolated from human vagina on cervical tumor cells (HeLa). Anaerobe. 2017;47:137–44. https://doi.org/10.1016/j.anaerobe.2017.05.013.CrossRefPubMed

73.

Zadravec P, Štrukelj B, Berlec A. Improvement of LysM-Mediated Surface Display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus species. Appl Environ Microbiol. 2015;81(6):2098–106. https://doi.org/10.1128/AEM.03694-14.CrossRefPubMedPubMedCentral

74.

Homburg C, Bommer M, Wuttge S, et al. Inducer exclusion in Firmicutes: insights into the regulation of a carbohydrate ATP binding cassette transporter from Lactobacillus casei BL23 by the signal transducing protein P-Ser46-HPr. Mol Microbiol. 2017;105(1):25–45. https://doi.org/10.1111/mmi.13680.CrossRefPubMed

75.

Wang K, Xu D, Wang B, et al. Inhibitory effect of vaginal Lactobacillus supernatants on cervical Cancer cells. Probiotics Antimicrob Proteins. 2018;10(2):236–42. https://doi.org/10.1007/s12602-017-9339-x.CrossRefPubMed

76.

Motevaseli E, Shirzad M, Akrami SM, et al. Normal and tumour cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate. J Med Microbiol. 2013;62(7):1065–72. https://doi.org/10.1099/jmm.0.057521-0.CrossRefPubMed

77.

Freitas AC, Hill JE. Quantification, isolation and characterization of Bifidobacterium from the vaginal microbiomes of reproductive aged women. Anaerobe. 2017;47:145–56. https://doi.org/10.1016/j.anaerobe.2017.05.012.CrossRefPubMed

78.

Mei L, Wang T, Chen Y, et al. Dysbiosis of vaginal microbiota associated with persistent high-risk human papilloma virus infection. J Transl Med. 20223;20(1):12. https://doi.org/10.1186/s12967-021-03201-w.

79.

Kim WG, Kim HI, Kwon EK, et al. Lactobacillus plantarum LC27 and Bifidobacterium longum LC67 mitigate alcoholic steatosis in mice by inhibiting LPS-mediated NF-kappaB activation through restoration of the disturbed gut microbiota. Food Funct. 2018;9(8):4255–65. https://doi.org/10.1039/c8fo00252e.CrossRefPubMed

80.

Kim DE, Kim JK, Han SK, et al. Lactobacillus plantarum NK3 and Bifidobacterium longum NK49 alleviate bacterial vaginosis and osteoporosis in mice by suppressing NF-κB-Linked TNF-α expression. J Med Food. 2019;22(10):1022–31. https://doi.org/10.1089/jmf.2019.4419.CrossRefPubMed

81.

Tilborghs S, Corthouts J, Verhoeven Y, et al. The role of Nuclear factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol. 2017;120:141–50. https://doi.org/10.1016/j.critrevonc.2017.11.001.CrossRefPubMed

82.

Esposito MM, Patsakos S, Borruso L. The role of the mycobiome in women’s Health. J Fungi (Basel). 2023;9(3):348. https://doi.org/10.3390/jof9030348.CrossRefPubMed

83.

Machado A, Cerca N. Influence of Biofilm formation by Gardnerella vaginalis and other Anaerobes on bacterial vaginosis. J Infect Dis. 2015;212(12):1856–61. https://doi.org/10.1093/infdis/jiv338.CrossRefPubMed

84.

Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017;595(2):451–63. https://doi.org/10.1113/JP271694.CrossRefPubMed

85.

Nicolò S, Antonelli A, Tanturli M, et al. Bacterial species from vaginal microbiota differently affect the production of the E6 and E7 oncoproteins and of p53 and p-Rb oncosuppressors in HPV16-Infected cells. Int J Mol Sci. 2023;24(8). https://doi.org/10.3390/ijms24087173.

86.

Kyrgiou M, Moscicki AB. Vaginal microbiome and cervical cancer. Semin Cancer Biol. 2022;86(Pt 3):189–98. https://doi.org/10.1016/j.semcancer.2022.03.005.CrossRefPubMed

87.

Anton L, Ferguson B, Friedman ES, et al. Gardnerella vaginalis alters cervicovaginal epithelial cell function through microbe-specific immune responses. Microbiome. 2022;10(1):119. https://doi.org/10.1186/s40168-022-01317-9.CrossRefPubMedPubMedCentral

88.

Kurnia I, Rauf S, Hatta M, et al. Molecular patho-mechanisms of cervical cancer (MMP1). Ann Med Surg (Lond). 2022;77:103415. https://doi.org/10.1016/j.amsu.2022.103415.CrossRefPubMed

89.

Rajagopala SV, Vashee S, Oldfield LM, et al. The human microbiome and Cancer. Cancer Prev Res (Phila). 2017;10(4):226–34. https://doi.org/10.1158/1940-6207.CAPR-16-0249.CrossRefPubMed

90.

Piyathilake CJ, Ollberding NJ, Kumar R, et al. Cervical Microbiota Associated with higher Grade Cervical Intraepithelial Neoplasia in Women infected with high-risk human papillomaviruses. Cancer Prev Res (Phila). 2016;9(5):357–66. https://doi.org/10.1158/1940-6207.CAPR-15-0350.CrossRefPubMed

91.

Molina MA, Andralojc KM, Huynen MA, et al. In-depth insights into cervicovaginal microbial communities and hrHPV infections using high-resolution microbiome profiling. NPJ Biofilms Microbiomes. 2022;8(1):75. https://doi.org/10.1038/s41522-022-00336-6.CrossRefPubMedPubMedCentral

92.

Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, et al. Cervical Microbiome and Cytokine Profile at various stages of cervical Cancer: a pilot study. PLoS ONE. 2016;11(4):e153274. https://doi.org/10.1371/journal.pone.0153274.CrossRef

93.

Norenhag J, Du J, Olovsson M, et al. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG. 2019;127(2):171–80. https://doi.org/10.1111/1471-0528.15854.CrossRefPubMed

94.

Brotman RM, Shardell MD, Gajer P, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014;210(11):1723–33. https://doi.org/10.1093/infdis/jiu330.CrossRefPubMedPubMedCentral

95.

Usyk M, Zolnik CP, Castle PE, et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog. 2020;16(3):e1008376. https://doi.org/10.1371/journal.ppat.1008376.CrossRefPubMedPubMedCentral

96.

Di Paola M, Sani C, Clemente AM, et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk human papillomavirus infection. Sci Rep. 2017;7(1):10200. https://doi.org/10.1038/s41598-017-09842-6.CrossRefPubMedPubMedCentral

97.

Nilsen T, Swedek I, Lagenaur LA, et al. Novel selective inhibition of Lactobacillus iners by Lactobacillus-Derived Bacteriocins. Appl Environ Microbiol. 2020;86(20):e1520–94. https://doi.org/10.1128/AEM.01594-20.CrossRef

98.

Sharifian K, Shoja Z, Jalilvand S. The interplay between human papillomavirus and vaginal microbiota in cervical cancer development. Virol J. 2023;20(1):73. https://doi.org/10.1186/s12985-023-02037-8.CrossRefPubMedPubMedCentral

99.

Basavaprabhu HN, Sonu KS, Prabha R. Mechanistic insights into the action of probiotics against bacterial vaginosis and its mediated preterm birth: an overview. Microb Pathog. 2020;141:104029. https://doi.org/10.1016/j.micpath.2020.104029.CrossRefPubMed

100.

Witkin SS, Mendes-Soares H, Linhares IM, et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. mBio. 2013;4(4):e413–60. https://doi.org/10.1128/mBio.00460-13.CrossRef

101.

Tachedjian G, Aldunate M, Bradshaw CS, et al. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol. 2017;168(9–10):782–92. https://doi.org/10.1016/j.resmic.2017.04.001.CrossRefPubMed

102.

Zheng N, Guo R, Wang J, et al. Contribution of Lactobacillus iners to Vaginal Health and diseases: a systematic review. Front Cell Infect Microbiol. 2021;11:792787. https://doi.org/10.3389/fcimb.2021.792787.CrossRefPubMedPubMedCentral

103.

Beghini J, Linhares IM, Giraldo PC, et al. Differential expression of lactic acid isomers, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-8 in vaginal fluid from women with vaginal disorders. BJOG. 2015;122(12):1580–5. https://doi.org/10.1111/1471-0528.13072.CrossRefPubMed

104.

Ragaliauskas T, Plečkaitytė M, Jankunec M, et al. Inerolysin and vaginolysin, the cytolysins implicated in vaginal dysbiosis, differently impair molecular integrity of phospholipid membranes. Sci Rep. 2019;9(1):10606. https://doi.org/10.1038/s41598-019-47043-5.CrossRefPubMedPubMedCentral

105.

Nowak RG, Randis TM, Desai P, et al. Higher levels of a cytotoxic protein, Vaginolysin, in Lactobacillus-Deficient Community State Types at the Vaginal Mucosa. Sex Transm Dis. 2018;45(4):e14–7. https://doi.org/10.1097/OLQ.0000000000000774.CrossRefPubMedPubMedCentral

106.

Colbert LE, El AM, Wang R, et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023;41(11):1945–62. https://doi.org/10.1016/j.ccell.2023.09.012.CrossRefPubMed

107.

Aldunate M, Srbinovski D, Hearps AC, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front Physiol. 2015;6:164. https://doi.org/10.3389/fphys.2015.00164.CrossRefPubMedPubMedCentral

108.

Laniewski P, Herbst-Kralovetz MM. Bacterial vaginosis and health-associated bacteria modulate the immunometabolic landscape in 3D model of human cervix. NPJ Biofilms Microbiomes. 2021;7(1):88. https://doi.org/10.1038/s41522-021-00259-8.CrossRefPubMedPubMedCentral

109.

Liu C, Li J, Shi W, et al. Progranulin regulates inflammation and tumor. Antiinflamm Antiallergy Agents Med Chem. 2020;19(2):88–102. https://doi.org/10.2174/1871523018666190724124214.CrossRefPubMedPubMedCentral

110.

Usyk M, Schlecht NF, Pickering S, et al. molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. Nat Commun. 2022;13(1):233. https://doi.org/10.1038/s41467-021-27628-3.CrossRefPubMedPubMedCentral

111.

Ravel J, Moreno I, Simón C. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gynecol. 2021;224(3):251–7. https://doi.org/10.1016/j.ajog.2020.10.019.CrossRefPubMed

112.

Lee JE, Lee S, Lee H, et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS ONE. 2013;8(5):e63514. https://doi.org/10.1371/journal.pone.0063514.CrossRefPubMedPubMedCentral

113.

Plisko O, Zodzika J, Jermakova I, et al. Aerobic vaginitis—underestimated risk factor for cervical intraepithelial neoplasia. Diagnostics (Basel). 2021;11(1):97. https://doi.org/10.3390/diagnostics11010097.CrossRefPubMed

114.

Wang C, Fan A, Li H, et al. Vaginal bacterial profiles of aerobic vaginitis: a case-control study. Diagn Microbiol Infect Dis. 2020;96(4):114981. https://doi.org/10.1016/j.diagmicrobio.2019.114981.CrossRefPubMed

115.

Ilhan ZE, Łaniewski P, Thomas N, et al. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. 2019;44:675–90. https://doi.org/10.1016/j.ebiom.2019.04.028.CrossRefPubMedPubMedCentral

116.

Borgogna JC, Shardell MD, Santori EK, et al. The vaginal metabolome and microbiota of cervical HPV-positive and HPV‐negative women: a cross‐sectional analysis. BJOG. 2019;127(2):182–92. https://doi.org/10.1111/1471-0528.15981.CrossRefPubMedPubMedCentral

117.

Srinivasan S, Morgan MT, Fiedler TL, et al. Metabolic signatures of bacterial vaginosis. mBio. 2015;6(2):e204–15. https://doi.org/10.1128/mBio.00204-15.CrossRef

118.

Liu L, Chen Y, Chen J, et al. Integrated metagenomics and metabolomics analysis of third-trimester pregnant women with premature membrane rupture: a pilot study. Ann Transl Med. 2021;9(23):1724. https://doi.org/10.21037/atm-21-5539.CrossRefPubMedPubMedCentral

119.

Nelson TM, Borgogna JL, Brotman RM, et al. Vaginal biogenic amines: biomarkers of bacterial vaginosis or precursors to vaginal dysbiosis? Front Physiol. 2015;6:253. https://doi.org/10.3389/fphys.2015.00253.CrossRefPubMedPubMedCentral

120.

Borgogna JC, Shardell MD, Grace SG, et al. Biogenic amines increase the odds of bacterial vaginosis and affect the growth of and lactic acid production by vaginal Lactobacillus spp. Appl Environ Microbiol. 2021;87(10):e3020–68. https://doi.org/10.1128/AEM.03068-20.CrossRef

121.

Fraszczak K, Barczynski B, Kondracka A. Does Lactobacillus exert a protective effect on the development of cervical and endometrial Cancer in women? Cancers (Basel). 2022;14(19):4909. https://doi.org/10.3390/cancers14194909.CrossRefPubMed

122.

Parada Venegas D, De la Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-Mediated gut epithelial and Immune Regulation and its relevance for inflammatory Bowel diseases. Front Immunol. 2019;10:277. https://doi.org/10.3389/fimmu.2019.00277.CrossRefPubMedPubMedCentral

123.

Delgado-Diaz DJ, Tyssen D, Hayward JA, et al. Distinct Immune responses elicited from Cervicovaginal Epithelial cells by Lactic Acid and short chain fatty acids Associated with Optimal and non-optimal vaginal microbiota. Front Cell Infect Microbiol. 2019;9:446. https://doi.org/10.3389/fcimb.2019.00446.CrossRefPubMed

124.

Mirzaei R, Kavyani B, Nabizadeh E, et al. Microbiota metabolites in the female reproductive system: focused on the short-chain fatty acids. Heliyon. 2023;9(3):e14562. https://doi.org/10.1016/j.heliyon.2023.e14562.CrossRefPubMedPubMedCentral

125.

Torcia M. Interplay among vaginal Microbiome, Immune Response and sexually transmitted viral infections. Int J Mol Sci. 2019;20(2):266. https://doi.org/10.3390/ijms20020266.CrossRefPubMedPubMedCentral

126.

Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80–6. https://doi.org/10.1126/science.aaa4972.CrossRefPubMedPubMedCentral

127.

Galdiero MR, Marone G, Mantovani A. Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol. 2018;10(8):a28662. https://doi.org/10.1101/cshperspect.a028662.CrossRef

128.

Jayshree RS. The Immune Microenvironment in Human Papilloma Virus-Induced Cervical lesions-evidence for Estrogen as an Immunomodulator. Front Cell Infect Microbiol. 2021;11:649815. https://doi.org/10.3389/fcimb.2021.649815.CrossRef

129.

Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355–77. https://doi.org/10.1016/j.cmet.2022.01.007.CrossRefPubMedPubMedCentral

130.

Shannon B, Gajer P, Yi TJ, et al. Distinct effects of the cervicovaginal microbiota and Herpes Simplex Type 2 infection on female genital Tract Immunology. J Infect Dis. 2017;215(9):1366–75. https://doi.org/10.1093/infdis/jix088.CrossRefPubMedPubMedCentral

131.

Hearps AC, Tyssen D, Srbinovski D, et al. Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol. 2017;10(6):1480–90. https://doi.org/10.1038/mi.2017.27.CrossRefPubMed

132.

McKenzie R, Maarsingh JD, Łaniewski P, et al. Immunometabolic Analysis of Mobiluncus mulieris and Eggerthella sp. Reveals Novel insights into their pathogenic contributions to the hallmarks of bacterial vaginosis. Front Cell Infect Microbiol. 2021;11:759697. https://doi.org/10.3389/fcimb.2021.759697.CrossRefPubMedPubMedCentral

133.

van Teijlingen NH, Helgers LC, Zijlstra-Willems EM, et al. Vaginal dysbiosis associated-bacteria megasphaera elsdenii and Prevotella timonensis induce immune activation via dendritic cells. J Reprod Immunol. 2020;138:103085. https://doi.org/10.1016/j.jri.2020.103085.CrossRefPubMed

134.

Liu CW, Su BC, Chen JY. Tilapia Piscidin 4 (TP4) reprograms M1 macrophages to M2 phenotypes in cell models of Gardnerella vaginalis-Induced Vaginosis. Front Immunol. 2021;12:773013. https://doi.org/10.3389/fimmu.2021.773013.CrossRefPubMedPubMedCentral

135.

Lin F, Zhang B, Shi Q, et al. The conditioned medium of Lactobacillus rhamnoides GG regulates Microglia/Macrophage polarization and improves functional recovery after spinal cord Injury in rats. Biomed Res Int. 2021;2021:3376496. https://doi.org/10.1155/2021/3376496.CrossRefPubMedPubMedCentral

136.

Kudela E, Liskova A, Samec M, et al. The interplay between the vaginal microbiome and innate immunity in the focus of predictive, preventive, and personalized medical approach to combat HPV-induced cervical cancer. EPMA J. 2021;12(2):199–220. https://doi.org/10.1007/s13167-021-00244-3.CrossRefPubMedPubMedCentral

137.

Arokiyaraj S, Seo SS, Kwon M, et al. Association of cervical microbial community with persistence, clearance and negativity of human papillomavirus in Korean women: a longitudinal study. Sci Rep. 2018;8(1):15479. https://doi.org/10.1038/s41598-018-33750-y.CrossRefPubMedPubMedCentral

138.

Deruaz M, Luster AD. Chemokine-mediated immune responses in the female genital tract mucosa. Immunol Cell Biol. 2015;93(4):347–54. https://doi.org/10.1038/icb.2015.20.CrossRefPubMed

139.

Jang SE, Jeong JJ, Choi SY, et al. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 attenuate Gardnerella vaginalis-infected bacterial vaginosis in mice. Nutrients. 2017;9(6):531. https://doi.org/10.3390/nu9060531.CrossRefPubMedPubMedCentral

140.

De Seta F, Campisciano G, Zanotta N, et al. The Vaginal Community State types Microbiome-Immune Network as key factor for bacterial vaginosis and aerobic vaginitis. Front Microbiol. 2019;10:2451. https://doi.org/10.3389/fmicb.2019.02451.CrossRefPubMedPubMedCentral

141.

Łaniewski P, Cui H, Roe DJ, et al. Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci Rep. 2019;9(1):7333. https://doi.org/10.1038/s41598-019-43849-5.CrossRefPubMedPubMedCentral

142.

Wei W, Xie LZ, Xia Q, et al. The role of vaginal microecology in the cervical cancer. J Obstet Gynaecol Res. 2022;48(9):2237–54. https://doi.org/10.1111/jog.15359.CrossRefPubMed

143.

Lebeau A, Bruyere D, Roncarati P, et al. HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nat Commun. 2022;13(1):1076. https://doi.org/10.1038/s41467-022-28724-8.CrossRefPubMedPubMedCentral

144.

Chen Y, Qiu X, Wang W, et al. Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. BMC Infect Dis. 2020;20(1):629. https://doi.org/10.1186/s12879-020-05324-9.CrossRefPubMedPubMedCentral

145.

Liu H, Liang H, Li D, et al. Association of Cervical Dysbacteriosis, HPV Oncogene expression, and cervical lesion progression. Microbiol Spectr. 2022;10(5):e15122. https://doi.org/10.1128/spectrum.00151-22.CrossRef

146.

Mitra A, MacIntyre DA, Ntritsos G, et al. The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat Commun. 2020;11(1):1999. https://doi.org/10.1038/s41467-020-15856-y.CrossRefPubMedPubMedCentral

147.

Mitra A, MacIntyre DA, Lee YS, et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep. 2015;5(1):16865. https://doi.org/10.1038/srep16865.CrossRefPubMedPubMedCentral

148.

Kang G, Jung D, Lee YH, et al. Potential Association between vaginal microbiota and cervical carcinogenesis in Korean women: a Cohort Study. Microorganisms. 2021;9(2):294. https://doi.org/10.3390/microorganisms9020294.CrossRefPubMedPubMedCentral

149.

Wang Z, Xiao R, Huang J, et al. The diversity of Vaginal Microbiota predicts Neoadjuvant Chemotherapy responsiveness in locally Advanced Cervical Cancer. Microb Ecol. 2022;84(1):302–13. https://doi.org/10.1007/s00248-021-01800-0.CrossRefPubMed

150.

Zhang H, Lu J, Lu Y, et al. Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in China. Sci Rep. 2018;8(1):4923. https://doi.org/10.1038/s41598-018-23389-0.CrossRefPubMedPubMedCentral

151.

Wiik J, Sengpiel V, Kyrgiou M, et al. Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study. BMC Womens Health. 2019;19(1):30. https://doi.org/10.1186/s12905-019-0727-0.CrossRefPubMedPubMedCentral

152.

Mitra A, MacIntyre DA, Paraskevaidi M, et al. The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasia. Genome Med. 2021;13(1):176. https://doi.org/10.1186/s13073-021-00977-w.CrossRefPubMedPubMedCentral

153.

Bai J, Jhaney I, Daniel G, et al. Pilot Study of Vaginal Microbiome using QIIME 2™ in Women with Gynecologic Cancer before and after Radiation Therapy. Oncol Nurs Forum. 2019;46(2):E48–59. https://doi.org/10.1188/19.ONF.E48-E59.CrossRefPubMed

154.

Tsementzi D, Pena Gonzalez A, Bai J, et al. Comparison of vaginal microbiota in gynecologic cancer patients pre- and post‐radiation therapy and healthy women. Cancer Med. 2020;9(11):3714–24. https://doi.org/10.1002/cam4.3027.CrossRefPubMedPubMedCentral

155.

Morris L, Do V, Chard J, et al. Radiation-induced vaginal stenosis: current perspectives. Int J Womens Health. 2017;9:273–9. https://doi.org/10.2147/IJWH.S106796.CrossRefPubMedPubMedCentral

156.

Chase D, Goulder A, Zenhausern F, et al. The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. Gynecol Oncol. 2015;138(1):190–200. https://doi.org/10.1016/j.ygyno.2015.04.036.CrossRefPubMed

157.

Chrysostomou D, Roberts LA, Marchesi JR, et al. Gut microbiota modulation of efficacy and toxicity of Cancer Chemotherapy and Immunotherapy. Gastroenterology. 2023;164(2):198–213. https://doi.org/10.1053/j.gastro.2022.10.018.CrossRefPubMed

158.

Santoni M, Piva F, Conti A, et al. Re: gut Microbiome influences Efficacy of PD-1-based Immunotherapy against epithelial tumors. Eur Urol. 2018;74(4):521–2. https://doi.org/10.1016/j.eururo.2018.05.033.CrossRefPubMed

159.

Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104–8. https://doi.org/10.1126/science.aao3290.CrossRefPubMedPubMedCentral

160.

Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9. https://doi.org/10.1126/science.aac4255.CrossRefPubMedPubMedCentral

161.

Wilkinson EM, Ilhan ZE, Herbst-Kralovetz MM. Microbiota–drug interactions: impact on metabolism and efficacy of therapeutics. Maturitas. 2018;112:53–63. https://doi.org/10.1016/j.maturitas.2018.03.012.CrossRefPubMed

162.

Wang M, Zhang L, Chang W, et al. The crosstalk between the gut microbiota and tumor immunity: implications for cancer progression and treatment outcomes. Front Immunol. 2023;13:1096551. https://doi.org/10.3389/fimmu.2022.1096551.CrossRefPubMedPubMedCentral

163.

Chilakapati SR, Ricciuti J, Zsiros E. Microbiome and cancer immunotherapy. Curr Opin Biotechnol. 2020;65:114–7. https://doi.org/10.1016/j.copbio.2020.02.007.CrossRefPubMed

164.

Secombe KR, Coller JK, Gibson RJ, et al. The bidirectional interaction of the gut microbiome and the innate immune system: implications for chemotherapy-induced gastrointestinal toxicity. Int J Cancer. 2019;144(10):2365–76. https://doi.org/10.1002/ijc.31836.CrossRefPubMed

165.

Lozenov S, Krastev B, Nikolaev G, et al. Gut Microbiome Composition and its metabolites are a key regulating factor for Malignant Transformation, Metastasis and Antitumor Immunity. Int J Mol Sci. 2023;24(6):5978. https://doi.org/10.3390/ijms24065978.CrossRefPubMedPubMedCentral

166.

Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–35. https://doi.org/10.1038/nri3430.CrossRefPubMed

167.

Wong S, Slavcev RA. Treating cancer with infection: a review on bacterial cancer therapy. Lett Appl Microbiol. 2015;61(2):107–12. https://doi.org/10.1111/lam.12436.CrossRefPubMed

168.

Kobayashi O, Taguchi A, Nakajima T, et al. Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer. Taiwan J Obstet Gynecol. 2024;63(1):22–8. https://doi.org/10.1016/j.tjog.2023.10.002.CrossRefPubMed

169.

Recine N, Palma E, Domenici L, et al. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case–control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis. Arch Gynecol Obstet. 2016;293(1):101–7. https://doi.org/10.1007/s00404-015-3810-2.CrossRefPubMed

170.

De Alberti D, Russo R, Terruzzi F, et al. Lactobacilli vaginal colonisation after oral consumption of Respecta® complex: a randomised controlled pilot study. Arch Gynecol Obstet. 2015;292(4):861–7. https://doi.org/10.1007/s00404-015-3711-4.CrossRefPubMed

171.

Ansari A, Son D, Hur YM, et al. Lactobacillus Probiotics improve Vaginal Dysbiosis in Asymptomatic Women. Nutrients. 2023;15(8):1862. https://doi.org/10.3390/nu15081862.CrossRefPubMedPubMedCentral

172.

Zeng M, Li X, Jiao X, et al. Roles of vaginal flora in human papillomavirus infection, virus persistence and clearance. Front Cell Infect Microbiol. 2023;12:1036869. https://doi.org/10.3389/fcimb.2022.1036869.CrossRefPubMedPubMedCentral

173.

Palma E, Recine N, Domenici L, et al. Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection. BMC Infect Dis. 2018;18(1):13. https://doi.org/10.1186/s12879-017-2938-z.CrossRefPubMedPubMedCentral

174.

Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med. 2019;25(10):1500–4. https://doi.org/10.1038/s41591-019-0600-6.CrossRefPubMed

175.

Kumar L, Dwivedi M, Jain N, et al. The Female Reproductive Tract Microbiota: friends and Foe. Life (Basel). 2023;13(6):1313. https://doi.org/10.3390/life13061313.CrossRefPubMed

176.

Vaneechoutte M, Guschin A, Van Simaey L, et al. Emended description of Gardnerella vaginalis and description of Gardnerella leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with delineation of 13 genomic species within the genus Gardnerella. Int J Syst Evol Microbiol. 2019;69(3):679–87. https://doi.org/10.1099/ijsem.0.003200.CrossRefPubMed

177.

Maarsingh JD, Łaniewski P, Herbst-Kralovetz MM. Immunometabolic and potential tumor-promoting changes in 3D cervical cell models infected with bacterial vaginosis-associated bacteria. Commun Biol. 2022;5(1):725. https://doi.org/10.1038/s42003-022-03681-6.CrossRefPubMedPubMedCentral

178.

Ahrodia T, Das S, Bakshi S, et al. Structure, functions, and diversity of the healthy human microbiome. Prog Mol Biol Transl Sci. 2022;191(1):53–82. https://doi.org/10.1016/bs.pmbts.2022.07.003.CrossRefPubMed

179.

Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45–53. https://doi.org/10.1016/j.maturitas.2017.06.025.CrossRefPubMed

Title: Cervicovaginal microbiota: a promising direction for prevention and treatment in cervical cancer
Authors: Jie Shen
Hao Sun
Jing Chu
Xiaodi Gong
Xiaojun Liu
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Human Papillomavirus
Cervical Cancer
Cervical Cancer
Respiratory Microbiota
Published in: Infectious Agents and Cancer / Issue 1/2024
Electronic ISSN: 1750-9378
DOI: https://doi.org/10.1186/s13027-024-00573-8

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Shared genetic factors and causal association between chronic hepatitis C infection and diffuse large B cell lymphoma

Hepatitis B virus reactivation in hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy combined with and without immunotherapy

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study

Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China

The causality between CD8+NKT cells and CD16−CD56 on NK cells with hepatocellular carcinoma: a Mendelian randomization study